Cited by 127Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Alzheimer's disease failed clinical trials

Asher, Shreya, Priefer, Ronny·2022·Life Sciences

DOI 10.1016/j.lfs.2022.120861

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is a progressive neurodegenerative disease typically presenting with symptoms of memory loss and cognitive decline. Existing theories for the causation of this focuses on amyloid beta plaques and neurofibrillary tau tangles. Most US Food and Drug Administration approved therapies for Alzheimer's disease target cognitive function. A multitude of clinical trials, with a variety of different targets have been conducted over the decades which have focused on the two clinical signs, with the only success being the controversial 2021 approval of an IgG1 anti-Ab antibody targeting the clearance of the Aβ plaques. Presented is a review of all previously failed Alzheimer's disease clinical trials and the rationale for their failures.

Integrity signals

Registry

Crossref · 10.1016/j.lfs.2022.120861

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
The Episodic Memory System: Neurocircuitry and Disorders
Dickerson, B. C., & Eichenbaum, H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.126 · Cited by 740
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723

Show all 61 references

Research works printed but not linked: 1

Schindowski, 2014, Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations, Degener. Neurol. Neuromuscul. Dis., 4, 121

Sorted by citations

The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 92
A coupled-GAN architecture to fuse MRI and PET image features for multi-stage classification of Alzheimer’s disease
Choudhury, C., Goel, T., & Tanveer, M. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102415 · Cited by 52
Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation?
Ruggiero, M., Calvello, R., Porro, C., Messina, G., Cianciulli, A., & Panaro, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112958 · Cited by 59
Ketogenic diet alleviates cognitive dysfunction and neuroinflammation in APP/PS1 mice via the Nrf2/HO-1 and NF-κB signaling pathways
Jiang, J., Pan, H., Shen, F., Tan, Y., & Chen, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373715 · Cited by 50
Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?
Balistreri, C. R., & Monastero, R. (2023) · Brain Sciences · doi:10.3390/brainsci14010019 · Cited by 47
Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier
Romero‐Ben, E., Goswami, U., Soto-Cruz, J., Mansoori-Kermani, A., Mishra, D., Martín‐Saldaña, S., Ugartemendia, J. M., Sosnik, A., Calderón, M., Beloqui, A., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.02.065 · Cited by 48
Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer’s disease
Guo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40
The microbiota–gut–brain axis in mental and neurodegenerative disorders: opportunities for prevention and intervention
Yassin, L. K., Skrabulyte-Barbulescu, J., Alshamsi, S. H., Saeed, S., Alkuwaiti, S. H., Almazrouei, S., Alnuaimi, A., BaniYas, S., Aldhaheri, D., Alderei, M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1667448 · Cited by 48
Molecular mechanism and therapeutic strategy of bile acids in Alzheimer’s disease from the emerging perspective of the microbiota–gut–brain axis
Wu, M., Cheng, Y., Zhang, R., Han, W., Jiang, H., Bi, C., Zhang, Z., Ye, M., Lin, X., & Liu, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117228 · Cited by 40
From Plaques to Pathways in Alzheimer’s Disease: The Mitochondrial-Neurovascular-Metabolic Hypothesis
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
Alzheimer's disease – Where do we go from here?
Борисович, Б. И. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.075 · Cited by 34
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Evaluating the efficacy and safety of Alzheimer’s disease drugs: A meta-analysis and systematic review
Chen, Y., Lai, M., & Tao, M. (2024) · Medicine · doi:10.1097/md.0000000000037799 · Cited by 36
Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease
Wang, Y., Xiong, B., Lin, H., Li, Q., Yang, H., Qiao, Y., Li, Q., Xu, Z., Lyu, W., Qu, W., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114806 · Cited by 32
Preclinical Research on Focused Ultrasound-Mediated Blood–Brain Barrier Opening for Neurological Disorders: A Review
Kong, C., & Chang, W. S. (2023) · Neurology International · doi:10.3390/neurolint15010018 · Cited by 33
Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?
Merighi, S., Travagli, A., Nigro, M., Pasquini, S., Cappello, M., Contri, C., Varani, K., Vincenzi, F., Borea, P. A., & Gessi, S. (2023) · Biomolecules · doi:10.3390/biom13060967 · Cited by 37
Cerebral organoids with chromosome 21 trisomy secrete Alzheimer’s disease-related soluble aggregates detectable by single-molecule-fluorescence and super-resolution microscopy
Fertan, E., Böken, D., Murray, A., Danial, J. S. H., Lam, J. Y. L., Wu, Y., Goh, P. A., Alić, I., Cheetham, M. R., Lobanova, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02333-3 · Cited by 31
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
A nasally administrated reactive oxygen species-responsive carrier-free gene delivery nanosystem for Alzheimer's disease combination therapy
Chen, Y., Yang, X., Li, J., Luo, H., Huang, Q., Yang, W., Lei, T., Lü, Y., Gong, Q., Li, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113604 · Cited by 30
White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimer’s disease (AD) neuropathology: A hypothesis and review
Sharp, F. R., DeCarli, C. S., Jin, L., & Zhan, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1096206 · Cited by 33
Curculigoside, a traditional Chinese medicine monomer, ameliorates oxidative stress in Alzheimer's disease mouse model via suppressing ferroptosis
Gong, Y., Wang, Y., Li, Y., Weng, F., Chen, T., & He, L. (2024) · Phytotherapy Research · doi:10.1002/ptr.8152 · Cited by 26
D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer’s disease
Hou, K., Pan, H., Shahpasand‐Kroner, H., Hu, C. J., Abskharon, R. N. N., Seidler, P. M., Mekkittikul, M., Balbirnie, M., Lantz, C., Sawaya, M. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl2991 · Cited by 26
Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities
Liang, T., Xie, Z., Dang, B., Wang, J., Zhang, T., Luan, X., Lu, T., Cao, C., & Chen, X. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129148 · Cited by 26
Probiotic Bifidobacterium breve MCC1274 Protects against Oxidative Stress and Neuronal Lipid Droplet Formation via PLIN4 Gene Regulation
Bernier, F., Kuhara, T., & Xiao, J. (2023) · Microorganisms · doi:10.3390/microorganisms11030791 · Cited by 27
Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
Alrouji, M., Alshammari, M. S., Syed, T., & Shamsi, A. (2025) · Antioxidants · doi:10.3390/antiox14070774 · Cited by 21
Unveiling tomorrow: Carbonic anhydrase activators and inhibitors pioneering new frontiers in Alzheimer's disease
Mishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 21
Positive Allosteric Modulator of SERCA Pump NDC-1173 Exerts Beneficial Effects in Mouse Model of Alzheimer’s Disease
Dahl, R. S., Moore, A. C., Knight, C., Mauger, C., Zhang, H., Schiltz, G. E., Koss, W. A., & Борисович, Б. И. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311057 · Cited by 21
Hyperphosphorylated Tau Inflicts Intracellular Stress Responses that Are Mitigated by Apomorphine
Song, Z., Wang, K., Hagar, H. C., Chen, H., Kuan, C.-Y., Zhang, K., & Kuo, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03689-x · Cited by 23
An enquiry to the role of CB1 receptors in neurodegeneration
Fernández‐Moncada, I., Eraso‐Pichot, A., Tor, T. D., Fortunato-Marsol, B., & Marsicano, G. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106235 · Cited by 23
Inflammatory role of S100A8/A9 in the central nervous system non-neoplastic diseases
Tian, Q., Li, Z., Yan, Z., Jiang, S., Zhao, X., Wang, L., & Li, M. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111100 · Cited by 19
Using focused ultrasound to modulate microglial structure and function
Grewal, S., de Andrade, E. G., Kofoed, R. H., Matthews, P. M., Aubert, I., Tremblay, M., & Morse, S. V. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1290628 · Cited by 19
Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease
Seplovich, G., Bouchi, Y., Vaccari, J. P. D. R., Pareja, J. C. M., Reisner, A., Blackwell, L. S., Mechref, Y. S., Wang, K., Tyndall, J. A., Tharakan, B., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00107 · Cited by 21
S100A9 protein activates microglia and stimulates phagocytosis, resulting in synaptic and neuronal loss
Pampuščenko, K., Jankevičiūtė, S., Morkūnienė, R., Šulskis, D., Smirnovas, V., Brown, G. C., & Borutaitė, V. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106817 · Cited by 20
Sex-based differences in effector cells of the adaptive immune system during Alzheimer's disease and related dementias
Lutshumba, J., Wilcock, D. M., Monson, N. L., & Stowe, A. M. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106202 · Cited by 20
SERCA pump as a novel therapeutic target for treating neurodegenerative disorders
Dahl, R. S., & Борисович, Б. И. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150748 · Cited by 18
Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer’s disease
Mojarad-Jabali, S., & Roh, K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125055 · Cited by 17
Donanemab: Not two without a third
Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/172673 · Cited by 18
Inhibition of CXXC5 function rescues Alzheimer’s disease phenotypes by restoring Wnt/β-catenin signaling pathway
Yoon, M., Kim, H., Shin, H., Lee, H., Kang, M., Park, S., Han, G., Kim, Y. S., & Choi, K. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106836 · Cited by 15
Coffee, antioxidants, and brain inflammation
Rai, S. P., Ansari, A. H., Singh, D., & Singh, S. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.06.005 · Cited by 20
Unconventional protein secretion (UPS): role in important diseases
Meldolesi, J. (2023) · Molecular Biomedicine · doi:10.1186/s43556-022-00113-z · Cited by 15
Paradigm shift required for translational research on the brain
Yoon, J. H., Lee, D., Lee, C., Cho, E., Lee, S., Cazenave‐Gassiot, A., Kim, K., Chae, S., Dennis, E. A., & Suh, P. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01218-x · Cited by 14
Ceria nanocluster-based therapy for Alzheimer’s disease through the modulation of activated microglia and attenuation of amyloid-β deposition
Liu, H.-J., Wang, M., Wang, Y., Shi, S., Hu, X., Zhang, D.-B., Fan, D., Mintzer, J., & Xu, P. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100158 · Cited by 13
Network-Medicine-Guided Drug Repurposing for Alzheimer’s Disease: A Multi-Dimensional Systems Pharmacology Approach
Akgüller, Ö., Balcı, M. A., & Cioca, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010003 · Cited by 13
Towards a Unitary Hypothesis of Alzheimer’s Disease Pathogenesis
Área-Gómez, E., & Schon, E. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231318 · Cited by 18
Emerging roles for ITAM and ITIM receptor signaling in microglial biology and Alzheimer's disease‐related amyloidosis
Samuels, J. D., Lukens, J. R., & Price, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15981 · Cited by 13
Targeting Inflammation in Alzheimer’s Disease: Insights Into Pathophysiology and Therapeutic Avenues-A Comprehensive Review
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 14
MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment
Petrović, N., Essack, M., Sami, A. S., Perry, G. L., Gojobori, T., Isenović, E. R., & Bajić, V. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107925 · Cited by 12
Enhancing Therapeutic Efficacy of Donepezil, an Alzheimer’s Disease Drug, by Diplazium esculentum (Retz.) Sw. and Its Phytochemicals
Inthachat, W., Chantong, B., Pitchakarn, P., Takoon, C., Karinchai, J., Suttisansanee, U., & Temviriyanukul, P. (2024) · Pharmaceuticals · doi:10.3390/ph17030341 · Cited by 14
Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents
Mạnh, N. V., Hoang, V.-H., Ngo, V. T. H., Kang, S., Jeong, J. J., Ha, H.-J., Kim, H., Kim, Y.-H., Ann, J., & Lee, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114837 · Cited by 12
Recent advances in understanding Alzheimer’s Disease: diagnosis and management strategies
Marín, A., & Budson, A. E. (2023) · Faculty Reviews · doi:10.12703/r/12-24 · Cited by 12
Mitochondria-targeting Cu2-xSe-TPP with dual enzyme activity alleviates Alzheimer's disease by modulating oxidative stress
Wang, L., Yuan, X., Cai, Q., Chen, Y., Jia, Z., Mai, Q., Liu, J., & Liu, Y. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114244 · Cited by 11
MFIFN: A multimodal feature interaction fusion network-based model for Alzheimer’s disease classification
Huang, Y., Liu, J., Li, Z., & Zhang, Q. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.107857 · Cited by 11
Investigating Genetic Overlap between Alzheimer’s Disease, Lipids, and Coronary Artery Disease: A Large-Scale Genome-Wide Cross Trait Analysis
Kirby, A., Porter, T., Adewuyi, E. O., & Laws, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168814 · Cited by 11
Alzheimer’s disease diagnosis from MRI and SWI fused image using self adaptive differential evolutionary RVFL classifier
Goel, T., Verma, S., Tanveer, M., & Suganthan, P. N. (2025) · Information Fusion · doi:10.1016/j.inffus.2024.102917 · Cited by 10
Potential modulation of microglial ferroptosis by Linggui Zhugan decoction in Alzheimer's disease through IL-17 and TNF pathways
Tang, P., Zhao, D., Lin, H., Li, X., Shi, C., Li, P., & Chen, H. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115489 · Cited by 11
Selecting Multitarget Peptides for Alzheimer’s Disease
Kasus‐Jacobi, A., Washburn, J. L., Laurence, R. B., & Pereira, H. A. (2022) · Biomolecules · doi:10.3390/biom12101386 · Cited by 10
Genetic analysis of cognitive preservation in the midwestern Amish reveals a novel locus on chromosome 2
Main, L. R., Song, Y. E., Lynn, A., Laux, R. A., Miskimen, K. L. S., Osterman, M. D., Cuccaro, M. L., Ogrocki, P. K., Lerner, A. J., Vance, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14045 · Cited by 8
AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies
Duechs, M. J., Blazevic, D., Rechtsteiner, P., Kenny, C. H., Lamla, T., Low, S. H. H., Savistchenko, J., Neumann, M., Melki, R., Schönberger, T., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00542-9 · Cited by 12
Validation and comparison of virtual reality and 3D mobile games for cognitive assessment against ACE-III in 82 young participants
Bhargava, Y., Kottapalli, A., & Baths, V. (2024) · Scientific Reports · doi:10.1038/s41598-024-75065-1 · Cited by 13
Design and Feasibility Analysis of a Smartphone‐Based Digital Cognitive Assessment Study in the Framingham Heart Study
Sunderaraman, P., Anda‐Duran, I. D., Karjadi, C., Peterson, J. J., Ding, H., Devine, S., Shih, L. C., Popp, Z., Low, S., Hwang, P. H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031348 · Cited by 7
A Positive Allosteric Modulator of the SERCA Pump Rescues Hippocampal Neuronal Circuits Dysfunction and Cognitive Defects in a Mouse Model of Alzheimer's Disease
Gerasimov, E., Rakovskaya, A., Pchitskaya, E. I., Власова, О. Л., Dahl, R. S., & Борисович, Б. И. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2337-24.2025 · Cited by 10
Audiogenic Seizures in the Streptozotocin-Induced Rat Alzheimer’s Disease Model
Alves, S. S., de Oliveira, J. A. C., Lazarini-Lopes, W., Servilha‐Menezes, G., Grigório-de-Sant’Ana, M., Vecchio, F. D., Mazzei, R. F., Almeida, S. S., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230153 · Cited by 8
Experience of Youths and Older People With Virtual Reality Games for Cognitive Assessment: Inductive Thematic Analysis and Insights for Key Stakeholders
Bhargava, Y., & Baths, V. (2024) · JMIR XR and spatial computing. · doi:10.2196/59197 · Cited by 8
Nucleosome assembly protein 1-like 5 alleviates Alzheimer’s disease-like pathological characteristics in a cell model
Wang, B. J., Liu, W., & Sun, F.-X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1034766 · Cited by 8
Unrevealing role of TLRs/NLRP receptors in halting Alzheimer's neuroinflammation: Current progress and existing therapies
Upadhayay, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116285 · Cited by 7
P2Y1 receptor in Alzheimer’s disease
Luo, S., Wang, Y., & Hisatsune, T. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02103 · Cited by 8
Alternative Pharmacological Strategies for the Treatment of Alzheimer’s Disease: Focus on Neuromodulator Function
Cunliffe, G., Lim, Y. T., Chae, W., & Jung, S. (2022) · Biomedicines · doi:10.3390/biomedicines10123064 · Cited by 6
A Comparative Study Using Deep Learning Models And Transfer Learning for Detection And Classification of Alzheimer’s Disease
Dawood, A. S. (2024) · Iraqi Journal of Computer Communication Control and System Engineering · doi:10.33103/uot.ijccce.24.1.5 · Cited by 6
Apolipoprotein E genotype-dependent accumulation of amyloid β in APP-knock-in mouse model of Alzheimer's disease
Takebayashi, Y., Yamazaki, Y., Yamada, H., Yazawa, K., Nakamori, M., Kurashige, T., Morino, H., Takahashi, T., Sotomaru, Y., & Maruyama, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.038 · Cited by 6
Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease
Tassinari, E., & Milelli, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00681c · Cited by 5
Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies
Morgan, D., & Lamb, B. T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13566 · Cited by 4
Towards a lifelong personalized brain health program: empowering individuals to define, pursue, and monitor meaningful outcomes
Saunders, S., Gomes‐Osman, J., Jannati, A., Ciesla, M. R., Banks, R., Showalter, J., Terrera, G. M., Luz, S. F., Ritchie, C. W., & Pascual‐Leone, Á. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1387206 · Cited by 5
Carnosine Mitigates Cognitive Impairment and Dopamine Release in an Okadaic Acid-Induced Zebrafish Model with Alzheimer’s Disease-like Symptoms
Chern, H., Caruso, G., Desaire, H., & Jarošová, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00596 · Cited by 6
Bile acids as therapeutic agents
Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 5
Designed inhibitors to reduce amyloid virulence and cytotoxicity and combat neurodegenerative and infectious diseases
Indig, R. Y., & Landau, M. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102318 · Cited by 7
The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma
Caniceiro, A. B., Agostinho, S. P., Piochi, L. F., Rosário‐Ferreira, N., & Moreira, I. S. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71131 · Cited by 4
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy
Sun, Z., Zhang, B., Smith, S. M., Atan, D., Khawaja, A. P., Stuart, K. V., Luben, R., Biradar, M. I., McGillivray, T., Patel, P. J., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16288 · Cited by 3
Sorl1 knockout inhibits expression of brain-derived neurotrophic factor: involvement in the development of late-onset Alzheimer's disease.
Zhao, M., Chen, X., Liu, J., Feng, Y., Wang, C., Xu, T., Liu, W., Liu, X., Liu, M., & Hou, D. (2024) · PubMed Central · doi:10.4103/1673-5374.387975 · Cited by 4
Calcium Signaling and Pathogenesis of Neurodegenerative Disorders: Potential Therapeutic OpportunitiesPreprint
Борисович, Б. И. (2026) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041758 · Cited by 4
Development of Delta Opioid Receptor Antagonists Which Prevent Alzheimer’s Disease-Like Pathology in the 5X-Familial Alzheimer’s Disease [5XFAD] Mouse Model
Tanguturi, P., Mitchell, S., Moukha‐Chafiq, O., Zhang, S., Tillotson, J., Ananthan, S., Augelli‐Szafran, C. E., & Streicher, J. M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00509 · Cited by 3
Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Neurodegeneration in Alzheimer’s Disease Mice Model 5xFAD
Gerasimov, E., Berg, M., Bolshakova, A. V., Борисович, Б. И., & Власова, О. Л. (2025) · Neural Plasticity · doi:10.1155/np/9880933 · Cited by 3
Intranasal delivery of Odorranalectin-modified lipid nanoparticles for multi-targeted therapy of Alzheimer's disease
Zhang, Y., Yin, C., Tian, Y., Li, X., Wang, H., Han, S., Chen, H., & Hou, H. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102764 · Cited by 3
From Molecular Networks to Medicines: Targeting Complexity in Alzheimer’s Disease (AD) Therapy
Kumar, D. R. P., Patel, S., Mishra, P. S., Srivastava, S., Sridhar, S. B., Shareef, J., Sahu, R., Tariq, M., Uddin, J., & Muhsinah, A. B. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05909-6 · Cited by 3
The potential of circulating nonesterified fatty acids and sphingolipids in the biological understanding of cognitive decline and dementia
Moseholm, K. F., Meineche, J. T., & Jensen, M. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000968 · Cited by 3
Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3β to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer’s Disease
He, J., Sun, S., Wang, H., Ying, Z., & Tam, K. Y. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01354-y · Cited by 3
Investigation of the Effects of Acacetin on Autophagy Pathway and Exosome Release in Amyloid Beta Peptide-Induced Toxicity Models
Ercin, N., Beşli, N., Johnson, B. S., Cakmak, R. K., Beker, M., Beker, M. Ç., & Kılıç, Ü. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04908-3 · Cited by 4
Multi-enzyme active CeVO4 nanocubes targetedly reverse apoptosis in AD neurons: Dual pathway mechanism of mitochondrial homeostasis reconstruction and oxidative stress regulation
Cai, Q., Yang, Y., Yang, Y., Zhou, Y., Liu, Y., PeiyaoWu, Yang, F., Liu, J., & Liu, J. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.168781 · Cited by 3
Harnessing Passive Pulsatile Shear Stress for Alzheimer’s Disease Prevention and Intervention
Adams, J. A., Uryash, A., & Lopez, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231010 · Cited by 3
Lecanemab (Leqembi): an amyloid beta monoclonal antibody approved for the treatment of Alzheimer’s disease
Sang, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00035-2 · Cited by 3
Disease-Modifying Drugs for Alzheimer’s Disease: Bending the Curve
Arshad, F., & Alladi, S. (2025) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_748_25 · Cited by 2
Resource-stratified machine learning framework for cognitive status classification and mild cognitive impairment to dementia progression prediction
Yang, J., Ding, H., Amini, S., Hao, B., Karjadi, C., Au, R., & Paschalidis, I. C. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02006-7 · Cited by 2
Calibrating microglia states in Alzheimer’s disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies
Xing, J. F., Mu, K., Xue, Y., Yang, X., Zhang, D., Gao, W., Zhang, T., Yang, S., Wang, R., Zhang, W., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843978 · Cited by 2
Trends and hotspots in tea and Alzheimer's disease research from 2014 to 2023: A bibliometric and visual analysis
Meng, X., Cui, W., Liang, Q., Zhang, B., & Wei, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30063 · Cited by 2
A Pilot Study to Research Associations between Alzheimer’s Disease and Suicide: The Questionnaire FeasibilityPreprint
Rodrigues, J. F. R., Rodrigues, L. P., da Silva, K. C. A., Rubatino, F. V. M., Fischer, H., Rodrigues, F. C. P., Júnior, E. G., Barbosa, P. M. K., Payão, S. L. M., de Godoy, M. F., et al. (2024) · Preprints.org · doi:10.20944/preprints202405.1144.v1 · Cited by 2
Cascaded Multimodal Deep Learning in the Differential Diagnosis, Progression Prediction, and Staging of Alzheimer’s and Frontotemporal DementiaPreprint
Guarnier, G., Reinelt, J. D., Molloy, E. N., Mihai, P. G., Einaliyan, P., Valk, S. L., Modestino, A. E., Ugolini, M., Mueller, K., Wu, Q., et al. (2024) · medRxiv · doi:10.1101/2024.09.23.24314186 · Cited by 2
Constructing a prognostic risk model for Alzheimer’s disease based on ferroptosis
Wang, X., Zhai, R.-Q., Li, Z., Li, H.-Q., Lei, Y.-T., Zhao, F.-F., Hao, X.-X., Wang, S., & Wu, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1168840 · Cited by 1
Urinary formic acid is associated with cerebral amyloid deposition and glucose metabolism in memory clinic patients
Wang, Y., Zhu, L., He, K., Cui, L., Pan, F., Guan, Y., He, R., Xie, F., & Guo, Q. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309117 · Cited by 1
A Novel Brain-Targeting Nanoparticle Loaded with Biatractylolide and Its Protective Effect on Alzheimer’s Disease
Hu, Q., Liu, C., Tan, J., Wang, J., Yang, H., Liu, Y., Mao, H., Jiang, Z., Feng, X., & Tao, X. (2025) · Pharmaceuticals · doi:10.3390/ph18060809 · Cited by 1
Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer’s Disease
Jurcău, M. C., Iovanovici, D. C., Jurcău, A., Militaru, M., Udrea, R. B., Comanescu, A. D., & Nunkoo, V. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189009 · Cited by 2
Breaking the Alzheimer’s Treatment Stalemate: Synergistic Application Strategies of Nanomaterials and Pharmaceutical Agents
Gao, H., Cheng, F., Zhang, Z., Yan, B., Liao, P., Zhang, S., Li, D., Chen, F., & Lei, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05320-7 · Cited by 1

Authors: Asher, S., & Priefer, R.
Affiliations: Massachusetts College of Pharmacy and Health Sciences (US)
Corresponding author: Priefer, Ronny
ORCID: Priefer, Ronny
Venue: Life Sciences
Publisher: Elsevier BV
Published: 2022-10
Volume: 306
Pages: 120861
ISSN: 0024-3205 (ISSN-L)
DOI: 10.1016/j.lfs.2022.120861
OpenAlex: W4289732088
Cited by: 124
References: 61
Citations by year: 2026: 22 · 2025: 31 · 2024: 34 · 2023: 29 · 2022: 8
FWCI: 3.62
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Life Sciences (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, clinical trial failure, amyloid plaques, tau tangles, anti-amyloid therapy, anti-tau therapy, cognitive function, neurodegeneration, therapeutic target
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Amyloid beta-Peptides, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer's disease failed clinical trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks